advertisement
Nguyen V 30
Showing records 1 to 25 | Display all abstracts from Nguyen V98627 Comparative study of 2-year outcomes for Hydrus or iStent inject microinvasive glaucoma surgery implants with cataract surgery
Holmes DP
Clinical and Experimental Ophthalmology 2022; 50: 303-311
98867 Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry
Bhandari S
Ophthalmology and therapy 2022; 11: 797-810
98629 Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry
Hunt AR
British Journal of Ophthalmology 2023; 107: 842-848
98867 Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry
Gabrielle PH
Ophthalmology and therapy 2022; 11: 797-810
98627 Comparative study of 2-year outcomes for Hydrus or iStent inject microinvasive glaucoma surgery implants with cataract surgery
Clement CI
Clinical and Experimental Ophthalmology 2022; 50: 303-311
98629 Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry
Nguyen V
British Journal of Ophthalmology 2023; 107: 842-848
98627 Comparative study of 2-year outcomes for Hydrus or iStent inject microinvasive glaucoma surgery implants with cataract surgery
Nguyen V
Clinical and Experimental Ophthalmology 2022; 50: 303-311
98629 Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry
Arnold JJ
British Journal of Ophthalmology 2023; 107: 842-848
98867 Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry
Nguyen V
Ophthalmology and therapy 2022; 11: 797-810
98627 Comparative study of 2-year outcomes for Hydrus or iStent inject microinvasive glaucoma surgery implants with cataract surgery
Healey PR
Clinical and Experimental Ophthalmology 2022; 50: 303-311
98629 Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry
McAllister IL
British Journal of Ophthalmology 2023; 107: 842-848
98867 Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry
Daien V
Ophthalmology and therapy 2022; 11: 797-810
98629 Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry
Mehta H
British Journal of Ophthalmology 2023; 107: 842-848
98867 Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry
Viola F; Viola F
Ophthalmology and therapy 2022; 11: 797-810
98627 Comparative study of 2-year outcomes for Hydrus or iStent inject microinvasive glaucoma surgery implants with cataract surgery
Lim R
Clinical and Experimental Ophthalmology 2022; 50: 303-311
98629 Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry
Invernizzi A
British Journal of Ophthalmology 2023; 107: 842-848
98627 Comparative study of 2-year outcomes for Hydrus or iStent inject microinvasive glaucoma surgery implants with cataract surgery
White A
Clinical and Experimental Ophthalmology 2022; 50: 303-311
98867 Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry
Bougamha W; Young S
Ophthalmology and therapy 2022; 11: 797-810
98629 Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry
Ponsioen T
British Journal of Ophthalmology 2023; 107: 842-848
98627 Comparative study of 2-year outcomes for Hydrus or iStent inject microinvasive glaucoma surgery implants with cataract surgery
Yuen J
Clinical and Experimental Ophthalmology 2022; 50: 303-311
98867 Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry
Romero-Nuñez B
Ophthalmology and therapy 2022; 11: 797-810
98629 Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry
Gabrielle PH
British Journal of Ophthalmology 2023; 107: 842-848
98627 Comparative study of 2-year outcomes for Hydrus or iStent inject microinvasive glaucoma surgery implants with cataract surgery
Lawlor M
Clinical and Experimental Ophthalmology 2022; 50: 303-311
98867 Dexamethasone Implant for Diabetic Macular Oedema: 1-Year Treatment Outcomes from the Fight Retinal Blindness! Registry
Figueras-Roca M
Ophthalmology and therapy 2022; 11: 797-810
98629 Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry
O'Toole L; Kusenda P
British Journal of Ophthalmology 2023; 107: 842-848